The Efficacy and Safety of Incisional Preemptive Analgesia Using Loxoprofen Sodium Patch in Patients Undergoing Thoracoscopic Surgery: a Multi-center Randomized Controlled Trial.

Video-assisted thoracoscopic surgery (VATS) is less invasive compared to traditional thoracotomy, but it is still reported that the incidence of acute pain following VATS exceeds 80%. Inadequate postoperative analgesia may trigger a series of adverse physiological stress responses, increase the occurrence of postoperative complications, and affect the rehabilitation process. If acute pain is not managed promptly and sufficiently, nearly one-quarter of patients may develop chronic pain, impacting normal life and sleep quality after discharge. Acute pain after VATS is mainly caused by the release of inflammatory mediators after soft tissue injury at the surgical site, which activates peripheral pain receptors and leads to abnormal action potentials transmitted along A δ and C fibers. Inflammatory mediators released from the soft tissues around incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization. Therefore, drugs with potent local anti-inflammatory properties such as Loxoprofen Sodium may play a key role in preventing or reducing postoperative pain. The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in VATS patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in VATS patients, promoting rapid recovery after VATS.

Start Date01 Jun 2026

Sponsor / Collaborator

Beijing Tiantan Hospital

NCT07591207

/ Not yet recruitingNot ApplicableIIT

The Efficacy and Safety of Incisional Preemptive Analgesia Using Loxoprofen Sodium Patch in Patients Undergoing Laparoscopic Surgery: a Multi-center Randomized Controlled Trial.

Studies have shown that up to 80% of patients experience postoperative pain following laparoscopic surgery due to inflammation caused by surgical incisions and surrounding tissues, necessitating pharmacological relief. Inflammatory mediators released from the soft tissues around laparoscopic incisions not only significantly alters the chemical microenvironment at the peripheral terminals of nociceptors, directly inducing pain, but also sensitizes afferent fibers, contributing to peripheral sensitization.
The investigators conducted a multicenter, prospective, randomized controlled clinical study to explore the use of Loxoprofen Sodium Patch for preoperative local incision analgesia in laparoscopic surgery patients. The investigators aim to observe whether this method can effectively alleviate postoperative incision pain, reduce the dosage of postoperative analgesics and the side effects caused using postoperative analgesics, improve patient satisfaction, and provide new ideas for postoperative analgesia in laparoscopic surgery patients, promoting rapid recovery after laparoscopic surgery.

Start Date01 Jun 2026

Sponsor / Collaborator

Beijing Tiantan Hospital

CTR20261459

/ CompletedNot Applicable

洛索洛芬钠凝胶贴膏在健康试验参与者的生物等效性试验

[Translation] Bioequivalence study of loxoprofen sodium gel patch in participants of a health trial

考察健康试验参与者单次贴敷1贴由广东伊康纳斯生物医药科技股份有限公司提供，湖南方盛制药股份有限公司生产的洛索洛芬钠凝胶贴膏【受试制剂T，规格：100mg/贴】或1贴由LEAD CHEMICAL CO.,LTD持证的洛索洛芬钠凝胶膏【参比制剂R，商品名：LOXONIN PAP®，规格：100mg/贴】的药代动力学特征，评价两制剂的生物等效性和安全性，同时考察两制剂的粘附性及皮肤刺激性，为该受试制剂注册申请提供依据。

[Translation]

This study investigated the pharmacokinetic characteristics of a single application of either loxoprofen sodium gel patch (test formulation T, 100 mg/patch) provided by Guangdong ICONS Biopharmaceutical Technology Co., Ltd. and manufactured by Hunan Fang Sheng Pharmaceutical Co., Ltd., or a single application of loxoprofen sodium gel patch (reference formulation R, LOXONIN PAP®, 100 mg/patch) certified by LEAD CHEMICAL CO.,LTD. The bioequivalence and safety of the two formulations were evaluated, along with their adhesiveness and skin irritation, to provide a basis for the registration application of the test formulation.

Start Date29 Apr 2026

Sponsor / Collaborator

Runhe Biology Medicine Technology (Shantou Co. Ltd.

100 Clinical Results associated with Loxoprofen Sodium Hydrate

100 Translational Medicine associated with Loxoprofen Sodium Hydrate

100 Patents (Medical) associated with Loxoprofen Sodium Hydrate

614

Literatures (Medical) associated with Loxoprofen Sodium Hydrate

01 Jun 2026·INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED

Lower dosing of Loxoprofen in type two diabetics with bone fractures/surgeries; Distinction from common NSAIDs

Article

Author: Badaineh, Batool ; Alomari, Yaser A ; Bustanji, Yasser K ; Hamdan, Mohammad Q ; Al-Rawashdeh, Hatem F ; Issa, Ala Y ; Al-Samarat, Firas ; AlAjlouni, Jihad M

AIM:

To investigate the appropriateness of lower doses of loxoprofen in patients with type two diabetes (T2D) with bone fractures/surgeries in comparison to common NSAIDs.

METHODS:

The current study is a prospective cross-sectional study. A total of 174 patients treated for bone fractures/orthopedic surgeries were recruited from orthopedic outpatient clinics in Amman, Madaba, and University of Jordan Hospital. Risk stratifications were performed for cardiovascular (CV), gastrointestinal (GI), renal, and hepatic complications. We created in-depth comparisons of safety and effectiveness of common NSAIDs in alleviating postoperative/ fracture pain.

RESULTS:

All NSAIDs showed variable reductions in the numerical pain score (NPS) after four weeks. Loxoprofen was the only NSAID prescribed at lower daily doses of 60-120 mg. Loxoprofen resulted in the most reduction in NPS; the fastest onset of action; the least time to reach peak analgesia; decrease in nocturia and the strongest overall pain relief in bone fractures and postoperative pain, p < 0.05. Celecoxib had the highest variability in pain relief among the agents.

CONCLUSION:

Lower doses of loxoprofen provide an effective strategy to alleviate postoperative and bone fracture pain and increase patient satisfactions among T2D at lower systemic risks compared to other NSAIDs. Such low dosing approach provides a plausible balanced triad of safety, effectiveness and maximum bone healing which lead to maximum patient satisfaction.

24 Feb 2026·LANGMUIR

Intrinsic Structure of Lipoplexes Embedded in Polyelectrolyte Multilayers

Article

Author: Kampik, Vincent ; Krabbes, Maria ; Kaysser, Leonard ; Büttner, Mathilde ; Wölk, Christian ; Shen, Chen ; Schneck, Emanuel

The functionalization of surfaces with therapeutically applicable nucleic acid carriers provides promising strategies in biomedical research to develop therapies that focus on local nucleic acid delivery. One such approach is the embedding of lipoplexes (LPXs) in polysaccharide-based polyelectrolyte multilayers (PEMs). PEMs based on hyaluronic acid and chitosan lead to efficient embedding of customized LPX connected with good biological activity. However, although quantitative evaluation demonstrates LPX embedding, information about detailed characteristics of embedded LPXs has been missing. In this study, we used synchrotron-based grazing-incidence small-angle X-ray scattering to investigate the effects of the change in the chemical environment caused by the embedding into PEMs on the LPX's internal mesoscopic structure. While the lamellar character of the LPXs was preserved, the repeat distance was affected by embedding into polysaccharide-based coatings.

01 Feb 2026·International Journal of Surgery

Herbal analgesic patches versus NSAIDs in soft tissue injury management: real-world comparative effectiveness from a 35-center Chinese prospective cohort of 1378 participants

Article

Author: Zhu, Ying ; Feng, Bin ; Shen, Zhimin ; Weng, Xisheng ; Li, Dandan ; Li, Tian ; Yang, Xingdong ; Wang, Yingjie

Background::

Soft tissue injuries are common sports- and activity-related traumas that are traditionally managed with nonsteroidal anti-inflammatory drugs (NSAIDs). This study compared the efficacy and safety of a traditional Chinese herbal transdermal patch (GTP), NSAIDs, and their combinations in treating soft tissue injuries across 3-day, 1-week, and 2-week intervals.

Methods::

A multicenter prospective cohort of 1378 patients from 35 medical institutions was analyzed. Patients were assigned to one of five groups – GTP: once daily; selective COX-2 inhibitors (SCI): imrecoxib 100 mg twice daily, meloxicam 7.5 mg twice daily, celecoxib 200 mg twice daily, or etoricoxib 60 mg once daily; nonselective COX inhibitors (NSCI): ibuprofen 300 mg twice daily, loxoprofen sodium 60 mg three times daily, or diclofenac sodium 100 mg once daily, GTP + SCI, or GTP + NSCI – and evaluated via visual analog scale (VAS) scores (primary endpoint), time to recovery of joint mobility, time and rate of joint pain relief/resolution, and quality-of-life measures [EuroQol 5-Dimension 3-Level Questionnaire (EQ-5D-3L) and short form health Survey 36 (SF-36)]. GTP was applied topically, and NSAIDs were given orally. The duration of treatment was 14 days or until the patient’s pain resolved. Therapeutic dynamics were assessed via linear regression and repeated-measures ANOVA.

Results::

Compared with NSCI ( P = 0.014) and GTP + NSCI combination therapy ( P = 0.033), GTP monotherapy exhibited significantly superior analgesic efficacy, although it marginally underperformed against both the SCI ( P < 0.001) and the GTP + SCI regimens ( P = 0.467). No therapeutic synergy was observed for any combination treatment. The results of the joint mobility recovery time and time/rate of joint pain relief/resolution demonstrated a similar trend in analgesic efficacy. EQ-5D-3L analysis revealed that the NSCI and NSCI + GTP cohorts outperformed the GTP monotherapy cohort, which surpassed both the SCI and the GTP + SCI groups in terms of quality-of-life metrics. The SF-36 scores were not significantly different among the groups. The short-term safety profiles remained acceptable across all the GTP-based interventions, whether administered alone or with NSAIDs.

Conclusion::

GTP is a safe NSAIDs alternative, especially for patients with comorbidities. Monotherapy or a 2-week SCI-to-GTP transition is recommended because of the lack of combination synergy.

News (Medical) associated with Loxoprofen Sodium Hydrate

15 Apr 2026

·www.fiercepharma.com

In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory

Daiichi Sankyo Healthcare markets several popular over-the-counter treatments, such as the decades-old combination cold remedy Lulu and the anti-inflammatory pain and fever reducer Loxonin. With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer health business. Daiichi has entered an agreement with Japanese beverage giant Suntory Holdings to transfer all shares in its subsidiary, Daiichi Sankyo Healthcare, which markets (PDF) a slate of popular over-the-counter treatments, including the decades-old combination cold remedy Lulu and the anti-inflammatory pain and fever reducer Loxonin. The current deal framework places the transfer value at 246.5 billion Japanese yen (roughly $1.55 billion), Daiichi Sankyo said in an April 15 press release (PDF). As it stands, Daiichi plans to carry out the transfer in stages, starting with the handover of 30% of its consumer health subsidiary’s shares this June. The entire process is expected to wrap up by June 2029, according to the company. Daiichi Sankyo currently holds 100% of the shares in the healthcare unit being sold to Suntory. In its release, Daiichi framed the deal as a means to ensure growth for its over-the-counter drugs business, which has also branched out into areas like skincare, oral care and food products. In turn, Daiichi said that moving forward, it would drill down on its innovative medicines business, and “particularly the oncology business.” Daiichi Sankyo has asserted itself in recent years as a force to be reckoned with among antibody-drug conjugate (ADC) developers, thanks to the success of its two AstraZeneca-partnered products, Enhertu and Datroway. Enhertu has been cleared across breast, gastric and non-small cell lung cancer (NSCLC), plus HER2-positive solid tumors, while Datroway—first approved early last year—is indicated for certain patients with breast cancer and NSCLC. At the J.P. Morgan Healthcare Conference earlier this year, Daiichi CEO Hiroyuki Okuzawa set out the ambition for his company’s ADCs to cover 700,000 eligible patients by fiscal year 2030—an impressive leap from the 120,000 the company tallied for its 2025 fiscal year, which ended in March. Apart from Daiichi, a growing number of drugmakers have elected to part ways with their over-the-counter businesses in recent years. Most recently, Sanofi scooped up 10 billion euros last spring by selling a controlling stake in its consumer health business Opella to U.S. private equity firm Clayton, Dubilier & Rice. Prior to that, prominent consumer health spinouts have been charted by Johnson & Johnson with its Kenvue business and GSK via Haleon, among multiple other recent examples.

Drug ApprovalADCAcquisition

15 Apr 2026

·firstwordpharma.com

Biopharma bites: Daiichi offloads consumer health, plus Alloy's raise and Replimune's layoffs

Daiichi sheds consumer health unit for $1.6BAlloy lands $40M in fundingReplimune downsizes after second FDA rebuffDaiichi sheds consumer health unit for $1.6BDaiichi Sankyo is offloading its consumer healthcare unit to Japanese beverage and consumer products giant Suntory Holdings for an expected price of JPN246.5 billion ($1.6 billion).The transaction, which will be carried out in stages, begins with a 30% stake transfer in June and concludes in mid-2029, ultimately making the business, known as Daiichi Sankyo Healthcare, a wholly owned unit of Suntory.The move reflects Daiichi's effort to concentrate resources on its core innovative medicines business, particularly oncology, where it has a strong presence in antibody-drug conjugates such as Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), both partnered with AstraZeneca. The divestment comes as former Novartis drug development head John Tsai settles into his new role as Daiichi's global R&D chief after joining earlier this month.Daiichi said Suntory's strength in consumer products makes it a more natural long-term fit for the unit, which sells products like over-the-counter analgesic Loxonin (loxoprofen sodium) and cold remedy Lulu in Japan, and has been expanding overseas.-Anna BratulicAlloy lands $40M in fundingAlloy Therapeutics closed a $40-million series E on Wednesday from investors including 8VC, JIC Venture Growth Investments and Echo Capital. The fundraising values the biotechnology ecosystem company at $1 billion.Proceeds will be used by Alloy to deepen its core discovery services for antibodies, genetic medicines and cell therapies, whilst also expanding its downstream preclinical and clinical development services. In addition, the firm will accelerate its AI and machine learning integration.Since its founding in 2017, Alloy's collaborations have led to over 100 licensed therapeutic programmes, 22 of which have advanced to clinical development, including two drugs in Phase III. The firm's most recent deal with Biogen is focused on using its AntiClastic antisense oligonucleotide platform to advance antisense therapeutics against multiple undisclosed targets. -Matt DennisReplimune downsizes after second FDA rebuffDays after US regulators rejected its melanoma therapy for a second time, Replimune disclosed it will cut 63 Massachusetts jobs, according to a state Worker Adjustment and Retraining Notification (WARN) filing. The layoffs are scheduled between April 13 and April 24 and will affect the company's Woburn operations.The workforce reduction follows a complete response letter last Friday denying accelerated approval of RP1 (vusolimogene oderparepvec), Replimune's oncolytic virus therapy for advanced melanoma in combination with Bristol Myers Squibb's Opdivo (nivolumab). Regulators again concluded that the supporting IGNYTE trial didn't constitute an adequate and well-controlled study, reiterating earlier concerns about the trial design and interpretability. It is the second rejection for RP1 after an initial denial in mid-2025.Replimune has defended RP1, citing a 34% response rate and durability of response in clinical data, while also criticising what it called a "slow-moving" review process and "inconsistent" FDA communication. After the setback, CEO Sushil Patel warned there would be job cuts, saying the company would have to "substantially" scale back US manufacturing and explore strategic alternatives.-Anna Bratulic

AcquisitionPhase 3

24 Sep 2025

·www.einpresswire.com

Huateng Pharma to Highlight PEG Derivatives and Key Pharmaceutical Intermediates at CPHI Frankfurt 2025

CHANGSHA, HUNAN, CHINA, September 24, 2025 / EINPresswire.com / -- Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma) is pleased to announce its participation at CPHI Frankfurt 2025, the premier global event for the pharmaceutical industry. The company will showcase its extensive product portfolio and advanced manufacturing capabilities at Booth 4.1H64. Visitors to the booth will be able to explore: PEG Derivatives: Huateng Pharma provides a wide range of PEG derivatives, including: Monodispersed PEGs: mPEG36-PEG, N3-PEG11-NH2, OH-PEG6-COOH. Polydisperse PEGs: mPEG-pALD, DSPE-PEG-Mannose, HZ-PEG-HZ. Multi-arm PEGs: Y-shape PEGs, 4-arm PEGs, 8-arm PEGs. More PEG derivatives>> These derivatives are applied in ADC linker design, PROTAC conjugation, PEGylation, dye labeling, and nanoparticle stabilization. Pharmaceutical Intermediates: Huateng Pharma also supplies key intermediates for late-stage clinical and marketed APIs, including: Aficamten Intermediate: 1-Methyl-1H-Pyrazole-4-Carboxylic Acid (CAS 5952-92-1). Voxelotor Intermediate: 1-Isopropyl-1H-pyrazole-5-boronic acid, pinacol ester (CAS 1282518-60-8). Loxoprofen Intermediate: 2-(4-Bromomethyl-phenyl)-propionic acid (CAS 111128-12-2). More intermediates>> Fine Chemicals: Specialty ingredients such as Diethylamino Hydroxybenzoyl Hexyl Benzoate (UVA filter, CAS 302776-68-7), Tetrahydrocurcumin (antioxidant, CAS 36062-04-1), and Piroctone Olamine (anti-fungal, CAS 68890-66-4), etc. Veterinary APIs: Including Fluralaner, Afoxolaner, and Atipamezole HCl. The company operates a 5,000 m² R&D center equipped with nearly 100 advanced analytical and testing instruments, including 400 MHz NMR, LC/MS, HPLC, and GC systems. Its 34,000 m² GMP-compliant plant includes four multifunctional production workshops, 100,000-grade dust-free clean rooms, and more than 800 advanced facilities such as enamel reactors, stainless steel hydrogenation reactors, and nitrogen production systems. By integrating DCS and SIS digital systems, Huateng Pharma enables real-time process monitoring and seamless scale-up from lab to pilot to commercial production. “We look forward to welcoming industry professionals to our booth at CPHI Frankfurt 2025. This event is an excellent opportunity to present our product lines and discuss how Huateng Pharma can support global drug development with high-quality, scalable solutions,” said Sonia Lee, Head of business development at Huateng Pharma. Huateng Pharma invites all attendees to visit Booth 4.1H64 to learn more and explore potential collaborations. About Huateng Pharma Hunan Huateng Pharmaceutical Co., Ltd. is a world-leading supplier of PEG derivatives, pharmaceutical intermediates, fine chemicals, and veterinary APIs. With a comprehensive R&D center and state-of-the-art GMP-compliant manufacturing facilities, Huateng Pharma provides reliable solutions from laboratory research to large-scale commercial production. The company is committed to supporting the global pharmaceutical and biotechnology industries with high-quality products and technical expertise. Contact: sales@huatengusa.com Website: https://us.huatengsci.com Sonia Lee Hunan Huateng Pharmaceutical Co., Ltd. sales@huatengusa.com Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 Deals associated with Loxoprofen Sodium Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01709	Loxoprofen Sodium Hydrate	M01A	DB09212

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	South Korea	Korea Prime Pharm Co., Ltd.	03 Apr 2024
Inflammation	Japan	Daiichi Sankyo Co., Ltd.	01 Mar 1986
Pain	Japan	Daiichi Sankyo Co., Ltd.	01 Mar 1986

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post procedural inflammation	Phase 3	China	Guangzhou Aobo Medical Technology Co., Ltd.	25 Mar 2024
Post procedural inflammation	Phase 3	China	Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd.	25 Mar 2024
Osteoarthritis, Knee	Phase 3	China	Chongqing Pharmaceutical Research Institute Co., Ltd.	10 Apr 2017
Ocular inflammation	Phase 2	China	Guangzhou Aobo Medical Technology Co., Ltd.	30 Dec 2022
Ocular inflammation	Phase 2	China	Guangdong Lewwin Pharmaceutical Research Institute Co.,Ltd.	30 Dec 2022
Myalgia	Phase 2	United States	Lead Chemical Co., Ltd.	01 Oct 2015
Acute Bronchitis	Phase 1	China	Overseas Pharmaceuticals Ltd.	27 Dec 2024
Acute upper respiratory tract inflammation	Phase 1	China	Overseas Pharmaceuticals Ltd.	27 Dec 2024
Analgesia	Phase 1	China	Overseas Pharmaceuticals Ltd.	27 Dec 2024
Fever	Phase 1	China	Overseas Pharmaceuticals Ltd.	27 Dec 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05010707 (TREAT, CTgov)	Phase 2	-	39	Hormone Profile+Spironolactone+Transdermal patch (Transdermal Estradiol Plus Spironolactone)	flwxxhfdau(rjcgupghid) = gwlotvzdlb kdmfoapqyz (zgprhxdqda, 46.2) View more	-	26 Nov 2024
				Hormone Profile+Spironolactone+Daily Sublingual Tablet (Daily Sublingual Estradiol Plus Spironolactone)	flwxxhfdau(rjcgupghid) = mlvwntfebi kdmfoapqyz (zgprhxdqda, 61.3) View more
NCT02467504 (CTgov)	Phase 2	Rheumatoid Arthritis	47	Loxoprofen+Folic Acid+MTX+hrIL-2 active (Experimental)	fzhrjgpaqh = ovprymvjfj sknjpajtgd (hmccgebkiq, oyhtxwvoet - hciahsuetn) View more	-	09 Sep 2019
				hrIL-2 placebo+Loxoprofen+Folic Acid+MTX (Placebo Comparator)	fzhrjgpaqh = dmldffommj sknjpajtgd (hmccgebkiq, gvjbkusnkx - qctlwjqnqz) View more
NCT02831569 (CTgov)	Phase 3	Low Back Pain \| Trigeminal Neuralgia \| Periarthritis scapulohumeralis	80	Loxoprofen Sodium+Methocarbamol	vybnifujdd = kncwbzdpvi wsrtcjedvd (tqegdnqluk, wylukszozd - acirwiakhb) View more	-	20 Jul 2018
EULAR2016	Not Applicable	Ankylosing Spondylitis	70	Loxoprofen sodium hydrogel patch (LX-P)	hibfrrtnnd(hzfjbkattq) = spbambxtnb snemyzjwxx (kgzhzuvdch )	Positive	08 Jun 2016
				Loxoprofen sodium tablet (LX-T)	hibfrrtnnd(hzfjbkattq) = qoddtjugbe snemyzjwxx (kgzhzuvdch )
NCT00994461 (Pubmed \| Aliment Pharmacol Ther)	Phase 4	First line	190	Celecoxib 100 mg b.d.	jbjlsigmpr(igebicflld) = ueauoaynwj gnssyoigyd (leweaehwep )	Positive	01 Feb 2013
				Loxoprofen 60 mg t.d.s.	jbjlsigmpr(igebicflld) = tncacvjick gnssyoigyd (leweaehwep )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis